DAFTAR PUSTAKA - Diponegoro Universityeprints.undip.ac.id/50496/8/Eka_Aryani... · DAFTAR PUSTAKA 1. Creager M, Libby ... New York: Springer Seienee&Business Media; 2003.1-34p. 5

80

DAFTAR PUSTAKA

1. Creager M, Libby P. Peripheral Arterial Disease In: Mann DL, Zipes DP,

Libby P, Bonow RO, editors. Braunwald’s Heart Disease : A Textbook of

Cardiovascular Medicine. 10th ed. Philadelphia: Elsevier Saunders; 2015.

1312 p.

2. Antono D, Hamonangani R. Penyakit Arteri Perifer. In: Setiati S, editor.

Buku Ajar Ilmu Penyakit Dalam. 1st ed. Jakarta: InternaPublishing; 2014.

p. 1516–26.

3. Rhee SY, Kim YS. Peripheral Arterial Disease in Patients with Type 2

Diabetes Mellitus. 2015;283–90.

4. Coffman JD, Eberhardt RT. Peripheral Arterial Disease, Diagnosis and

Treatment. New York: Springer Seienee&Business Media; 2003.1-34p.

5. Rooke TW, Hirsch a. T, Misra S, Sidawy a. N, Beckman J a., Findeiss LK,

et al. 2011 ACCF/AHA Focused Update of the Guideline for the

Management of Patients With Peripheral Artery Disease. Circulation.

Elsevier Inc.; 2011;58(19):2020–45.

6. Fowkes FGR, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott

MM, et al. Comparison of global estimates of prevalence and risk factors

for peripheral artery disease in 2000 and 2010: a systematic review and

analysis. Lancet. Elsevier Ltd; 2013;382(9901):1329–40.

7. Selvin E. Prevalence of and Risk Factors for Peripheral Arterial Disease in

the United States: Results From the National Health and Nutrition

Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.

8. Fowkes FGR, Low LP, Tuta S, Kozak J. Ankle-brachial index and extent of

atherothrombosis in 8891 patients with or at risk of vascular disease:

Results of the international AGATHA study. Eur Heart J.

2006;27(15):1861–7.

9. Rhee SY, H G, ZM L, SW-K C, S W, P P. Multi-country study on the

prevalence and clinical features of peripheral arterial disease in Asian type

2 diabetes patients at high risk of atherosclerosis. Diabetes Res Clin Pract.

2007;76(1):82–92.

10. American Diabetes Association. Epidemiology and Impact of Peripheral

Arterial Disease in People with Diabetes. Diabetes Care.

2003;26(12):3333–41.

81

11. American Heart Association. What is peripheral vascular disease? In

American Heart Association; 2012.

12. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL,

et al. ACC/AHA 2005 Practice Guidelines for the Management of Patients

With Peripheral Arterial Disease (Lower Extremity, Renal, Mesenteric, and

Abdominal Aortic). Circulation. 2006;113(11):e463–5.

13. Norgren L, Hiatt WR, Dormandy J a., Nehler MR, Harris K a., Fowkes

FGR, et al. Inter-Society Consensus for the management of peripheral

arterial disease (TASC II). Int Angiol. 2007;26(2):82–157.

14. F Brian Boudi M. Coronary Artery Atherosclerosis Treatment &

Management. Medscape. 2016; [cited 2016 Jun 17]

15. Marso SP, Hiatt WR. Peripheral arterial disease in patients with diabetes. J

Am Coll Cardiol. 2006;47(5):921–9.

16. The Japan Diabetes Society. Evidence-based Practice Guideline for the

Treatment for Diabetes in Japan 2013. Diabet Med. 2013;1–3.

17. Ilmiah Populer [Internet]. [cited 2016 Jan 26]. Available from:

http://www.pdpersi.co.id/content/popular_science.php?psid=30

18. Dinas Kesehatan Jateng. Daftar Tabel Profil Kesehatan Provinsi Jawa

Tengah. Semarang: Dinkes Jateng; 2008. 38 p.

19. Huh JH, Choi E, Lim JS, Lee MY, Chung CH, Shin JY. Serum cystatin C

levels are associated with asymptomatic peripheral arterial disease in type 2

diabetes mellitus patients without overt nephropathy. Diabetes Res Clin

Pract. Elsevier Ireland Ltd; 2015;108(2):258–64.

20. Rahman A. Faktor – Faktor Risiko Mayor Aterosklerosis pada Berbagai

Penyakit Aterosklerosis di RSUP Dr. Kariadi Semarang. Diponegoro

University; 2012.

21. Tomeleri CM, Ronque ER, Silva DR, Cardoso Junior CG, Fernandes R a,

Teixeira DC, et al. Prevalence of dyslipidemia in adolescents: comparison

between definitions. Rev Port Cardiol. Sociedade Portuguesa de

Cardiologia; 2015;34(2):103–9.

22. Bittner V. Perspectives on dyslipidemia and coronary heart disease in

women: an update. Curr Opin Cardiol. 2006;21(6):602–7.

23. Fakhrzadeh H, Tabatabaei-malazy O. Dyslipidemia and Cardiovascular

Disease. Endocrinol Metab Res Cent Tehran Univ Med Sci. 2008;

82

24. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar

(RISKESDAS) 2007. Lap Nas 2007. 2008;1–384.

25. Rinandyta SA. Perbedaan Kadar LDL pada Penderita Diabetes Melitus

Tipe 2 dengan Hipertensi dan Tanpa Hipertensi di RSUD Dr. Moewardi.

Universitas Muhammadiyah Surakarta; 2012.

26. Ilminovia F. Hubungan antara Status Diabetes Melitus dengan Status

Penyakit Arteri Perifer (PAP) pada Pasien Hipertensi In Abstract Book

ESC 26th. European student congress; 2015.

27. Longo DL, Kasper DL, Jameson JL, Fauci AS, Hauser SL, Loscalzo J,

editors. Harrison’s Principles of Internal Medicine. 18th ed. New York: Mc

Graw Hill; 2012. 2066 p.

28. Agrawal K, Eberhardt RT. Contemporary Medical Management of

Peripheral Arterial Disease. Cardiol Clin. Elsevier Inc; 2015;33(1):111–37.

29. Runge MS, Greganti MA. Netter’s Internal Medicine. 2nd ed. Philadelphia:

Saunders Elsevier; 2009. 213 p.

30. McDermott, M M, McGrae. Lower Extremity Manifestations of Peripheral

Artery Disease. Am Hear Assoc J. 2015;115:1540–50.

31. Lozano FS, González-Porras JR, March JR, Lobos JM, Carrasco E, Ros E.

Diabetes mellitus and intermittent claudication: a cross-sectional study of

920 claudicants. Diabetol Metab Syndr. 2014;6:21.

32. Hallett Jr JW. Peripheral Arterial Disease. Merck Manuals. 2008;169–73.

33. Bordeaux LM, Reich LM, Hirsch AT. The Epidemiology and Natural.

Springer J. 2003;(Ic):21–35.

34. Baker. Smoking and Peripheral Arterial Disease ( PAD ). ASH Research

Report Smoking and Peripheral Arterial Disease. 2014;

35. Tendera M, Aboyans V, Bartelink M-L, Baumgartner I, Clement D, Collet

J-P, et al. ESC Guidelines on the diagnosis and treatment of peripheral

artery diseases: Document covering atherosclerotic disease of extracranial

carotid and vertebral, mesenteric, renal, upper and lower extremity arteries

* The Task Force on the Diagnosis and Treat. Eur Heart J.

2011;32(22):2851–906.

36. Olin JW, Sealove B a. Peripheral artery disease: current insight into the

disease and its diagnosis and management. Mayo Clin Proc.

2010;85(7):678–92.

83

37. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG. Peripheral

arterial disease detection, awarness and treatment in primary care. JAMA.

2001;286(11):1317–24.

38. Age AT. Peripheral Arterial Disease in the Legs. In: CdcGov. p. 4–5.

39. Hirsch AT, Haskal ZJ, Hertzer NR, Bakal CW, Creager MA, Halperin JL.

ACC/AHA 2005 practice guidelines for the Management of Patients with

Peripheral Arterial Disease (lower extremity, renal, mesenteric, and

abdominal aortic): a collaborative report from the American Association for

Vascular Surgery/Society for Vascular Sur. Circulation. 2006;113(11):463–

654.

40. Suyono S. Diabetes Melitus. In: Setiati S, editor. Buku Ajar Ilmu Penyakit

Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2315–418.

41. American Diabetes Association. Classification and Diagnosis of Diabetes.

Diabetes Care. 2015;38(Supplement_1):S8–16.

42. Hirsch a T, Hiatt WR. PAD awareness, risk, and treatment: new resources

for survival--the USA PARTNERS program. Vasc Med. 2001;6(3

Suppl):9–12.

43. Joshua A, Beckman, MD M, Mark A. Creager M, Peter Libby M. Diabetes

and Atherosclerosis Epidemiologi, Pathophysiology, and Management.

JAMA. 2002;(287):2570–81.

44. Coggins M, Lindner J, Rattigan S, Jahn L, Fasy E, Kaul S, et al. Muscle

Perfusion by Capillary Recruitment. 2001;50

45. Forstermann U, Sessa WC. Nitric oxide synthases: regulation and function.

European Heart Journal. 2012;33(7):829–37.

46. Hua L, Hongliang L, Yige B, Xiangxun Z, Yerong Y. Free Fatty Acids

Induce Endothelial Dysfunction and Activate Protein Kinase C and Nuclear

Factor-κB Pathway in Rat Aorta. Int J Cardiol. 152(2):218–24.

47. Erwinanto, Santoso A, Putranto JNE, Tedjasukmana P, Suryawan R, Rifqi

S, et al. Pedoman tatalaksana dislipidemia. 1st ed. Perhimpunan Dokter

Spesialis Kardiovaskular Indonesia; 2013.1-7p.

48. PERKENI. Konsensus Pengelolaan Dislipidemia di Indonesia. Jakarta:

Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran UI; 2012.15-

21p.

84

49. Fodor G. Primary prevention of CVD: Treating dyslipidemia. Am Fam

Physician. 2011;83(10):1207–8.

50. Adam JM. Dislipidemia. In: Setiati S, editor. Buku Ajar Ilmu Penyakit

Dalam. 1st ed. Jakarta: InternaPublishing; 2014. p. 2549–68.

51. Forouzandeh F, Salazar G, Patrushev N, Xiong S, Hilenski L, Fei B, et al.

Metformin beyond diabetes: Pleiotropic benefits of metformin in

attenuation of atherosclerosis. J Am Heart Assoc. 2014;3(6):1–12.

52. Jamkhande PG, Chandak PG, Dhawale SC, Barde SR, Tidke PS, Sakhare

RS. Therapeutic approaches to drug targets in atherosclerosis. Saudi Pharm

J SPJ Off Publ Saudi Pharm Soc. King Saud University; 2014;22(3):179–

90.

53. Elizabeth Klodas M. High Blood Pressure and Atherosclerosis. WebMD.

2016; [cited 2016 Jun 17]

54. Aboyans V, Criqui MH, Abraham P, Allison M a., Creager M a., Diehm C,

et al. Measurement and Interpretation of the Ankle-Brachial Index: A

Scientific Statement From the American Heart Association. Circulation.

2012;126(24):2890–909.

55. Mahameed A Al. Peripheral Arterial Disease. Cleve Clin J Med. 2009;

56. Bonham P, Cappuccio M, Hulsey T, Michel Y, Kelechi T, Jenkins C. Are

Ankle and Toe Brachial Indices (ABI-TBI) Obtained by a Pocket Doppler

Interchangeable With Those Obtained by Standard Laboratory Equipment?

J Wound, Ostomy Cont Nurs. 2007;34(1):35–44.

57. Carmo G a L, Mandil a, Nascimento BR, Arantes BD, Bittencourt JC,

Falqueto EB, et al. Can we measure the ankle-brachial index using only a

stethoscope? A pilot study. Fam Pract. 2009;26(1):22–6.

58. WOCN Wound Committee. Ankle Brachial Index. J Wound, Ostomy Cont

Nurs. 2012;39(April):S21–9.

59. Inada A, Weir GC, Bonner-Weir S. Induced ICER I?? down-regulates

cyclin a expression and cell proliferation in insulin-producing ?? cells.

Biochem Biophys Res Commun. 2005;329(3):925–9.

60. Yogiantoro M. Hipertensi Esensial. Buku Ajar Ilmu Penyakit Dalam Jilid

1. IV. Jakarta: FKUI; 2006. 610-14 p.

61. F Brian Boudi M. Treatment of Low HDL levels and High Triglyceride

levels in Patients With Diabetes. Medscape. 2016;[cited 2016 Jun 17]

85

62. Selvin E, Erlinger TP. Prevalence of and risk factors for peripheral arterial

disease in the United States: Results from the National Health and Nutrition

Examination Survey, 1999-2000. Circulation. 2004;110(6):738–43.

63. Pepine CJ, Handberg EM. The vascular biology of hypertension and

atherosclerosis and intervention with calcium antagonists and angiotensin-

converting enzyme inhibitors. Clin Cardiol. 2001;24(11 Suppl):V1–5.

86

Lampiran 1. Informed Consent (Persetujuan Pasien)

JUDUL PENELITIAN : Hubungan antara Dislipidemia dengan Derajat

Keparahan Penyakit Arteri Perifer (PAP) pada

Pasien Diabetes Melitus Tipe 2 Terkontrol Sedang.

INSTANSI PELAKSANA : Bagian Ilmu Penyakit Dalam FK Undip -

Mahasiswa Program Studi Strata-1 Kedokteran

Umum Fakultas Kedokteran Universitas

Diponegoro

PERSETUJUAN SETELAH PENJELASAN

(INFORMED CONSENT) Yth Bapak/Ibu …………………………………..

Nama saya Eka Aryani, saya mahasiswa Program Studi S1 Ilmu

Pendidikan Dokter Fakultas Kedokteran UNDIP. Saya melakukan penelitian

dengan judul “Hubungan antara Dislipidemia dengan Derajat Keparahan Penyakit

Arteri Perifer (PAP) pada Pasien Diabetes Melitus Tipe 2 Terkontrol Sedang”.

Tujuan dari penelitian ini adalah untuk mengetahui hubungan antara dislipidemia

dengan derajat keparahan penyakit arteri perifer (PAP) pada pasien DM tipe 2

terkontrol sedang. Dislipidemia adalah kelainan metabolisme lipid (lemak darah)

dimana terjadi peningkatan maupun penurunan komponen lipid seperti kolesterol

total, kolesterol LDL (Low Density Lipoprotein), TG (trigliserida), serta

menurunnya kolesterol HDL (High Density Lipoprotein) dalam darah. Penyakit

arteri perifer adalah gangguan suplai darah ke ekstremitas atas atau bawah

(tungkai atau lengan) karena obstruksi atau sumbatan sehingga timbul gejala

seperti rasa nyeri pada ekstremitas tersebut(klaudikasio intermiten). Bapak/Ibu

87

terpilih sebagai peserta penelitian ini. Apabila Bapak/Ibu setuju untuk menjadi

peserta penelitian maka ada beberapa hal yang akan Bapak/Ibu alami, yaitu:

- Pengambilan informasi nama, umur, jenis kelamin, status merokok, status

hipertensi dan keluhan yang dirasakan melalui wawancara

- Diukur tekanan darah pada kedua kaki dan kedua lengan pada saat istirahat

- Dan bila diperlukan, akan diukur tekanan darah pada kaki setelah berolah

raga naik-turun bangku selama 4-5 menit atau berjalan selama 6 menit atau

dorsofleksi plantarfleksi selama 6 menit.

Keuntungan bagi Bapak/Ibu yang bersangkutan ikut dalam penelitian ini

adalah mendapat fasilitas pendeteksian Penyakit Arteri Perifer (PAP) serta

mengetahui derajat PAP yang diderita apabila terdeteksi. Dengan dilakukanya

pendeteksian ini, kita dapat mengetahui apakah terdapat sumbatan pembuluh

darah pada lengan atau kaki Bapak/Ibu. Bapak/Ibu juga akan diberi pemahaman

mengenai PAP. Saya menjamin bahwa penelitian ini tidak akan menimbulkan

efek yang merugikan pada Bapak/Ibu. Dalam penelitian ini tidak ada intervensi

dalam bentuk apapun terhadap Bapak/ Ibu. Setiap data pemeriksaan dan penelitian

dijamin kerahasiaannya dengan tidak mencantumkan identitas subyek. Sebagai

peserta penelitian keikutsertaan ini bersifat sukarela dan tidak dikenakan biaya

penelitian.

Penanggung jawab penelitian:

Eka Aryani

085642702444

Sudah mendengar dan memahami penjelasan penelitian, dengan ini saya

menyatakan

SETUJU / TIDAK SETUJU

untuk ikut sebagai subyek/sampel penelitian ini.

Tegal, …………………….2016

Saksi

Nama Terang : Nama Terang :

Alamat : Alamat :

88

Lampiran 2

DAFTAR TILIK PENELUSURAN REKAM MEDIK

No Keterangan

Nama

Jenis Kelamin

Umur

Alamat

No HP

Kontrol teratur/tidak

Status merokok ya/ tidak

DM

Status glikemik (HbA1c):

Kadar gula darah terakhir

GDS:

GDP:

Lamanya DM:

Obat yang diminum:

Dislipidemia ya/ tidak

TC:

LDL:

HDL:

TG:

Lamanya dislipidemia:

Obat yang diminum:

Hipertensi

Tekanan darah terakhir:

Obat yang diminum:

89

Lampiran 3

LEMBAR PENGUMPULAN DATA

ANKLE-BRACHIAL INDEX (ABI)

Tanggal Pemeriksaan:

Nama Pasien: Umur:

Catatan:

Apakah ada aktivitas berat yang baru

saja dilakukan/ konsumsi kafein/

alkohol terakhir

Jenis Kelamin:

ABI saat istirahat

Kanan Pengukuran Rata-

rata

Kiri Pengukuran Rata-

rata I II I II

Brachialis Brachialis

Tibialis

Posterior

Tibialis

Posterior

Dorsalis

Pedis

Dorsalis

Pedis

ABI kanan = rata − rata tertinggi tekanan sistolik kaki kanan DP atau TP

rata − rata tertinggi tekanan sistolik lengan kanan atau kiri

ABI kiri = rata − rata tertinggi tekanan sistolik kaki kiri DP atau TP

rata − rata tertinggi tekanan sistolik lengan (kanan atau kiri)

Nilai ABI saat istirahat =

90

ABI setelah exercise

(Diakukan apabila nilai ABI saat istirahat normal namun terdapat gejala

klaudikasio)

Lamanya exercise =

Nilai tekanan sistolik kaki setelah exercise =

Nilai ABI setelah exercise =

Kelengkapan Data

Status Merokok :

Lamanya DM :

Lamanya Dislipidemia

Minum obat hipertensi teratur atau tidak :

Minum obat diabetes teratur atau tidak :

Minum obat dislipidemia teratur atau tidak :

91

Lampiran 4. Izin Penelitian

92

93

Lampiran 5. Dokumentasi Penelitian

94

95

Lampiran 6. Biodata Mahasiswa

Identitas

Nama Lengkap : Eka Aryani

Jenis Kelamin : Perempuan

Program Studi : Pendidikan Dokter

NIM : 22010112110093

Tempat, tanggal lahir : Tegal, 14 Februari 1995

E-mail : [email protected]

Nomor telepon/HP : 085642702444

Riwayat Pendidikan Formal

SD SMP SMA S1

Nama Institusi SDN

Margadana 3

Kota Tegal

SMPN 18

Kota Tegal

SMAN 1 Kota

Tegal

Pendidikan

Dokter

Fakultas

Kedokteran

UNDIP

Tahun masuk-

lulus

2000-2006 2006-2009 2009-2012 2012

Organisasi yang Pernah Diikuti:

Lembaga Tahun

Divisi Pengembangan Mahasiswa

Kelompok Studi Mahasiswa FK

UNDIP

2013-2014

Bidang Riset HIMA KU UNDIP 2012-2014

Kelompok Ilmiah Remaja SMAN 1

Kota Tegal

2010-2012

Pengalaman Mengikuti Lomba Karya Ilmiah

Potensi Teng-teng Natto sebagai Alternatif Terapi Aterosklerosis, LKTI-GT Mini

Scientific Fair 2014, Peserta Terbaik.

mailto:[email protected]

96

Lampiran 7. Hasil SPSS

Frequencies

Frequency Table

Status Dislipidemia

Frequency Percent Valid Percent Cumulative

Percent

Valid

ya 21 70,0 70,0 70,0

tidak 9 30,0 30,0 100,0

Total 30 100,0 100,0

Jenis kelamin


Percent

Valid

Laki-laki 17 56,7 56,7 56,7

Perempuan 13 43,3 43,3 100,0

Total 30 100,0 100,0

Usia

N Valid 30

Missing 0

Mean 59,17

Median 58,50

Std. Deviation 7,250

Minimum 46

Maximum 71

Usia


Percent

Valid

46 2 6,7 6,7 6,7

50 2 6,7 6,7 13,3

51 1 3,3 3,3 16,7

52 1 3,3 3,3 20,0

53 2 6,7 6,7 26,7

54 2 6,7 6,7 33,3

55 2 6,7 6,7 40,0

57 1 3,3 3,3 43,3

58 2 6,7 6,7 50,0

59 1 3,3 3,3 53,3

62 1 3,3 3,3 56,7

97

64 3 10,0 10,0 66,7

65 2 6,7 6,7 73,3

66 2 6,7 6,7 80,0

67 3 10,0 10,0 90,0

68 2 6,7 6,7 96,7

71 1 3,3 3,3 100,0

Total 30 100,0 100,0

Status merokok


Percent

Valid

Ya 6 20,0 20,0 20,0

pasif 5 16,7 16,7 36,7

mantan 3 10,0 10,0 46,7

tidak 16 53,3 53,3 100,0

Total 30 100,0 100,0

Hipertensi


Percent

Valid

Ya 13 43,3 43,3 43,3

Tidak 17 56,7 56,7 100,0

Total 30 100,0 100,0

Penyakit atherosclerosis lain


Percent

Valid

Ya 7 23,3 23,3 23,3

Tidak 23 76,7 76,7 100,0

Total 30 100,0 100,0

Crosstabs

Case Processing Summary

Cases

Valid Missing Total

N Percent N Percent N Percent

Status Dislipidemia * Status

PAP

30 100,0% 0 0,0% 30 100,0%

98

Status Dislipidemia * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

Status Dislipidemia

ya

Count 12 9 21

Expected Count 8,4 12,6 21,0

% within Status PAP 100,0% 50,0% 70,0%

% of Total 40,0% 30,0% 70,0%

tidak

Count 0 9 9



% of Total 0,0% 30,0% 30,0%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

Chi-Square Tests

Value df Asymp. Sig. (2-

sided)

Exact Sig. (2-

sided)

Exact Sig. (1-

sided)

Pearson Chi-Square 8,571a 1 ,003

Continuity Correctionb 6,356 1 ,012

Likelihood Ratio 11,699 1 ,001

Fisher's Exact Test ,004 ,003

Linear-by-Linear Association 8,286 1 ,004

N of Valid Cases 30

a. 1 cells (25,0%) have expected count less than 5. The minimum expected count is 3,60.

b. Computed only for a 2x2 table

Risk Estimate

Value 95% Confidence Interval

Lower Upper

For cohort Status PAP =

Tidak

,429 ,262 ,702

N of Valid Cases 30

99

T-Test

Group Statistics

Status PAP N Mean Std. Deviation Std. Error Mean

Kolesterol total Ya 12 212,00 45,798 13,221

Tidak 9 164,33 34,077 11,359

Independent Samples Test

Levene's

Test for

Equality of

Variances

t-test for Equality of Means

F Sig. t df Sig. (2-

tailed)

Mean

Differenc

e

Std.

Error

Differenc

e

95% Confidence

Interval of the

Difference

Lower Upper

Kolester

ol total

Equal variances

assumed

1,62

2

,218 2,61

9

19 ,017 47,667 18,199 9,577 85,757

Equal variances

not assumed

2,73

5

18,999 ,013 47,667 17,430 11,184 84,149

T-Test

Group Statistics


LDL Ya 12 136,83 31,007 8,951

Tidak 9 104,44 30,566 10,189


Levene's Test for

Equality of

Variances



tailed)

Mean

Differenc

e

Std.

Error

Differenc

e

95% Confidence

Interval of the

Difference

Lower Upper

LDL

Equal variances

assumed

,042 ,840 2,383 19 ,028 32,389 13,591 3,942 60,836

Equal variances

not assumed

2,388 17,52

3

,028 32,389 13,562 3,841 60,937

100

T-Test

Group Statistics


HDL Ya 12 25,58 9,549 2,756

Tidak 9 33,67 5,074 1,691

NPar Tests

Mann-Whitney Test

Ranks

Status PAP N Mean Rank Sum of Ranks

Trigliserida

Ya 12 13,42 161,00

Tidak 9 7,78 70,00

Total 21

Test Statisticsa

Trigliserida

Mann-Whitney U 25,000

Wilcoxon W 70,000

Z -2,061

Asymp. Sig. (2-tailed) ,039

Exact Sig. [2*(1-tailed Sig.)] ,041b

a. Grouping Variable: Status PAP

b. Not corrected for ties.


Levene's Test for

Equality of Variances



tailed)

Mean

Differenc

e

Std. Error

Differenc

e

95% Confidence

Interval of the

Difference

Lower Upper

HDL

Equal variances

assumed

4,985 ,038 -

2,298

19 ,033 -8,083 3,517 -15,445 -,721

Equal variances

not assumed

-

2,499

17,44

3

,023 -8,083 3,234 -14,893 -1,273

101

Crosstabs


Cases

Valid Missing Total


jumlah dislipidemia * Status PAP 21 100,0% 0 0,0% 21 100,0%

jumlah dislipidemia * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

jumlah dislipidemia

1 komponen

Count 0 6 6



% of Total 0,0% 28,6% 28,6%

2 komponen

Count 9 3 12



% of Total 42,9% 14,3% 57,1%

3 komponen

Count 2 0 2

Expected Count 1,1 ,9 2,0


% of Total 9,5% 0,0% 9,5%

4 komponen

Count 1 0 1

Expected Count ,6 ,4 1,0


% of Total 4,8% 0,0% 4,8%

Total

Count 12 9 21



% of Total 57,1% 42,9% 100,0%

Chi-Square Tests


sided)




N of Valid Cases 21

a. 6 cells (75,0%) have expected count less than 5. The minimum expected count is

,43.

102

Frequencies

jenis komponen


Percent

Valid

HDL 4 19,0 19,0 19,0

TG 2 9,5 9,5 28,6

TC HDL 1 4,8 4,8 33,3

HDL TG 10 47,6 47,6 81,0

LDL HDL 1 4,8 4,8 85,7

TC LDL HDL 2 9,5 9,5 95,2

TC LDL HDL TG 1 4,8 4,8 100,0

Total 21 100,0 100,0

NPar Tests

Descriptive Statistics

N Mean Std.

Deviation

Minimum Maximum Percentiles

25th 50th

(Median)

75th

jenis

komponen

21 3,57 1,720 1 7 2,00 4,00 4,00

Status PAP 21 1,43 ,507 1 2 1,00 1,00 2,00

103

Mann-Whitney Test

Ranks

Status PAP N Mean Rank Sum of Ranks

jenis komponen

Ya 12 14,38 172,50

Tidak 9 6,50 58,50

Total 21

Test Statisticsa

jenis komponen

Mann-Whitney U 13,500

Wilcoxon W 58,500

Z -3,059

Asymp. Sig. (2-tailed) ,002

Exact Sig. [2*(1-tailed Sig.)] ,002b

a. Grouping Variable: Status PAP

b. Not corrected for ties.

Crosstabs


Cases

Valid Missing Total


Jenis kelamin * Status PAP 30 100,0% 0 0,0% 30 100,0%

Jenis kelamin * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

Jenis kelamin

Laki-laki

Count 6 11 17



% of Total 20,0% 36,7% 56,7%

Perempuan

Count 6 7 13



% of Total 20,0% 23,3% 43,3%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

104

Chi-Square Tests


sided)

Exact Sig. (2-

sided)

Exact Sig. (1-

sided)

Pearson Chi-Square ,362a 1 ,547

Continuity Correctionb ,051 1 ,821

Likelihood Ratio ,361 1 ,548


Linear-by-Linear Association ,350 1 ,554

N of Valid Cases 30



Risk Estimate


Lower Upper

Odds Ratio for Jenis kelamin

(Laki-laki / Perempuan)

,636 ,145 2,784

For cohort Status PAP = Ya ,765 ,320 1,828


Tidak

1,202 ,651 2,220

N of Valid Cases 30

T-Test

Group Statistics


Usia Ya 12 61,08 6,302 1,819

Tidak 18 57,89 7,722 1,820


Levene's Test for

Equality of

Variances



tailed)

Mean

Differenc

e

Std.

Error

Differenc

e

95% Confidence

Interval of the

Difference

Lower Upper

Usia

Equal variances

assumed

1,788 ,192 1,191 28 ,244 3,194 2,683 -2,300 8,689

Equal variances

not assumed

1,241 26,72

0

,225 3,194 2,574 -2,089 8,477

105

Crosstabs


Cases

Valid Missing Total


Status merokok * Status

PAP

30 100,0% 0 0,0% 30 100,0%

Status merokok * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

Status merokok

Ya

Count 4 2 6



% of Total 13,3% 6,7% 20,0%

pasif

Count 3 2 5



% of Total 10,0% 6,7% 16,7%

mantan

Count 1 2 3



% of Total 3,3% 6,7% 10,0%

tidak

Count 4 12 16



% of Total 13,3% 40,0% 53,3%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

Chi-Square Tests


sided)




N of Valid Cases 30

106

a. 6 cells (75,0%) have expected count less than 5. The minimum

expected count is 1,20.

Risk Estimate

Value

Odds Ratio for Status

merokok (Ya / pasif)

a

a. Risk Estimate statistics cannot be

computed. They are only computed for a

2*2 table without empty cells.

Crosstabs


Cases

Valid Missing Total


Hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%

Hipertensi * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

Hipertensi

Ya

Count 9 4 13



% of Total 30,0% 13,3% 43,3%

Tidak

Count 3 14 17



% of Total 10,0% 46,7% 56,7%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

107

Chi-Square Tests


sided)

Exact Sig. (2-

sided)

Exact Sig. (1-

sided)






N of Valid Cases 30



Risk Estimate


Lower Upper

Odds Ratio for Hipertensi

(Ya / Tidak)

10,500 1,889 58,359

For cohort Status PAP = Ya 3,923 1,320 11,656


Tidak

,374 ,161 ,869

N of Valid Cases 30

Crosstabs


Cases

Valid Missing Total



* Status PAP

30 100,0% 0 0,0% 30 100,0%

Penyakit atherosclerosis lain * Status PAP Crosstabulation

Status PAP Total

Ya Tidak


Ya

Count 4 3 7



% of Total 13,3% 10,0% 23,3%

Tidak Count 8 15 23


108


% of Total 26,7% 50,0% 76,7%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

Chi-Square Tests


sided)

Exact Sig. (2-

sided)

Exact Sig. (1-

sided)


Continuity Correctionb ,380 1 ,537




N of Valid Cases 30



Risk Estimate


Lower Upper

Odds Ratio for Penyakit

atherosclerosis lain (Ya /

Tidak)

2,500 ,445 14,037

For cohort Status PAP = Ya 1,643 ,701 3,849


Tidak

,657 ,266 1,626

N of Valid Cases 30

Crosstabs

Minum obat * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

Minum obat Teratur

Count 6 16 22



% of Total 20,0% 53,3% 73,3%

Tidak teratur Count 6 2 8

109



% of Total 20,0% 6,7% 26,7%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

Chi-Square Tests


sided)

Exact Sig. (2-

sided)

Exact Sig. (1-

sided)






N of Valid Cases 30



Risk Estimate


Lower Upper

Odds Ratio for Minum obat

(Teratur / Tidak teratur)

,125 ,020 ,799

For cohort Status PAP = Ya ,364 ,165 ,802


Tidak

2,909 ,853 9,925

N of Valid Cases 30

Crosstabs


Cases

Valid Missing Total


Obat dislipidemia * Status

PAP

30 100,0% 0 0,0% 30 100,0%

110

Obat dislipidemia * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

Obat dislipidemia

ya

Count 5 3 8



% of Total 16,7% 10,0% 26,7%

tidak

Count 7 8 15



% of Total 23,3% 26,7% 50,0%

tidak minum obat

Count 0 7 7



% of Total 0,0% 23,3% 23,3%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

Chi-Square Tests


sided)




N of Valid Cases 30



Risk Estimate

Value

Odds Ratio for Obat

dislipidemia (ya / tidak)

a




111

Crosstabs


Cases

Valid Missing Total


obat hipertensi * Status PAP 30 100,0% 0 0,0% 30 100,0%

obat hipertensi * Status PAP Crosstabulation

Status PAP Total

Ya Tidak

obat hipertensi

teratur

Count 5 2 7



% of Total 16,7% 6,7% 23,3%

tidak teratur

Count 4 2 6



% of Total 13,3% 6,7% 20,0%

tidak minum obat

Count 3 14 17



% of Total 10,0% 46,7% 56,7%

Total

Count 12 18 30



% of Total 40,0% 60,0% 100,0%

Chi-Square Tests


sided)




N of Valid Cases 30



112

Risk Estimate

Value

Odds Ratio for obat

hipertensi (teratur / tidak

teratur)

a




Logistic Regression


Unweighted Casesa N Percent

Selected Cases

Included in Analysis 30 100,0

Missing Cases 0 ,0

Total 30 100,0

Unselected Cases 0 ,0

Total 30 100,0

a. If weight is in effect, see classification table for the total number of cases.

Dependent Variable Encoding

Original Value Internal Value

Ya 0

Tidak 1

Categorical Variables Codings

Frequency Parameter coding

(1)

Minum obat Teratur 22 1,000

Tidak teratur 8 ,000

Hipertensi Ya 13 1,000

Tidak 17 ,000

Block 0: Beginning Block

Classification Tablea,b

Observed Predicted

Status PAP Percentage

Correct Ya Tidak

Step 0 Status PAP

Ya 0 12 ,0

Tidak 0 18 100,0

Overall Percentage 60,0

a. Constant is included in the model.

113

b. The cut value is ,500

Variables in the Equation

B S.E. Wald df Sig. Exp(B)

Step 0 Constant ,405 ,373 1,184 1 ,277 1,500

Variables not in the Equation

Score df Sig.

Step 0 Variables

Hipertensi(1) 8,167 1 ,004

obat_dm(1) 5,568 1 ,018

Overall Statistics 10,027 2 ,007

Block 1: Method = Backward Stepwise (Likelihood Ratio)

Omnibus Tests of Model Coefficients

Chi-square df Sig.

Step 1

Step 10,792 2 ,005

Block 10,792 2 ,005

Model 10,792 2 ,005

Step 2a

Step -2,303 1 ,129

Block 8,488 1 ,004

Model 8,488 1 ,004

a. A negative Chi-squares value indicates that the Chi-squares

value has decreased from the previous step.

Model Summary

Step -2 Log likelihood Cox & Snell R

Square

Nagelkerke R

Square

1 29,589a ,302 ,408

2 31,892a ,246 ,333

a. Estimation terminated at iteration number 4 because parameter

estimates changed by less than ,001.

Hosmer and Lemeshow Test

Step Chi-square df Sig.

1 ,070 2 ,966

2 ,000 0 .

114

Contingency Table for Hosmer and Lemeshow Test

Status PAP = Ya Status PAP = Tidak Total

Observed Expected Observed Expected

Step 1

1 5 5,124 1 ,876 6

2 4 3,876 3 3,124 7

3 1 ,876 1 1,124 2

4 2 2,124 13 12,876 15

Step 2 1 9 9,000 4 4,000 13

2 3 3,000 14 14,000 17

Classification Tablea

Observed Predicted

Status PAP Percentage

Correct Ya Tidak

Step 1 Status PAP

Ya 9 3 75,0

Tidak 4 14 77,8


Step 2 Status PAP

Ya 9 3 75,0

Tidak 4 14 77,8


a. The cut value is ,500

Variables in the Equation

B S.E. Wald df Sig. Exp(B) 95% C.I.for EXP(B)

Lower Upper

Step 1a

Hipertensi(1) -2,017 ,919 4,820 1 ,028 ,133 ,022 ,805

obat_dm(1) 1,552 1,048 2,190 1 ,139 4,719 ,604 36,836

Constant ,250 1,055 ,056 1 ,813 1,284

Step 2a

Hipertensi(1) -2,351 ,875 7,219 1 ,007 ,095 ,017 ,529

Constant 1,540 ,636 5,863 1 ,015 4,667

a. Variable(s) entered on step 1: Hipertensi, obat_dm.

115

Model if Term Removed

Variable Model Log

Likelihood

Change in -2 Log

Likelihood

df Sig. of the

Change

Step 1 Hipertensi -17,390 5,190 1 ,023

obat_dm -15,946 2,303 1 ,129

Step 2 Hipertensi -20,190 8,488 1 ,004

Variables not in the Equation

Score df Sig.

Step 2a

Variables obat_dm(1) 2,360 1 ,124

Overall Statistics 2,360 1 ,124

a. Variable(s) removed on step 2: obat_dm.

Documents

DAFTAR PUSTAKA - Diponegoro Universityeprints.undip.ac.id/50496/8/Eka_Aryani... · DAFTAR PUSTAKA 1. Creager M, Libby ... New York: Springer Seienee&Business Media; 2003.1-34p. 5